Amlexanox Side Effects: Safety Signals and Warnings
Amlexanox safety concerns are compound-specific. The main listed side effects are Diarrhea, Nausea, and Upper respiratory tract infection. The main warning signals are Oral use for metabolic indications is investigational - not FDA approved for this purpose, FDA-approved only as a topical treatment for canker sores, and Phase 2 trials showed variable efficacy, with some failing to meet primary endpoints.
Direct Answer
Amlexanox has a small Phase 2 human pilot showing metabolic improvement in a subset of obese insulin-resistant patients, but the trial was underpowered and the responder phenotype is not well-characterized. The IKKe/TBK1 mechanism is scientifically interesting as a non-GLP-1 weight-loss target. At this stage, amlexanox is more useful for mechanistic research into inflammatory obesity than as a standalone weight-loss protocol.
- Evidence grade
- Level C
- Research status
- Phase 2
- Category
- Weight Loss & Metabolic
- Best for
- IKKe/TBK1 pathway research, inflammatory obesity mechanistic studies, insulin resistance investigation
Reported Side Effects
- Diarrhea
- Nausea
- Upper respiratory tract infection
- Headache
- Contact dermatitis (topical use)
Warnings
- Oral use for metabolic indications is investigational - not FDA approved for this purpose
- FDA-approved only as a topical treatment for canker sores
- Phase 2 trials showed variable efficacy, with some failing to meet primary endpoints
- Long-term systemic safety data for oral administration is limited
Known or Plausible Interactions
- Other anti-inflammatory agents (potential additive immunosuppressive effects)
- Insulin and oral hypoglycemics (may enhance glucose-lowering effects)
Regulatory Context
FDA approved as a topical agent (Aphthasol) for aphthous ulcers. Systemic use for metabolic indications is investigational.
Evidence Snapshot
| Evidence grade | Level C |
|---|---|
| Research status | Phase 2 |
| Best supported outcomes | Insulin Sensitivity (Level C), Weight Loss (Level C), and Hepatic Steatosis Reduction (Level D) |
| Primary citation count | 2 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Amlexanox Side Effects: Safety Signals and Warnings." Last reviewed 2026-04-04. https://examinepeptides.com/answers/amlexanox-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.